Pharmaust Limited (AU:PAA) has released an update.
PharmAust Limited, a biotech firm advancing therapeutics for neurodegenerative diseases, has rescheduled its 2024 Annual General Meeting (AGM) to 9 October to accommodate the completion of necessary documentation following a transformative year. The company, which is repurposing monepantel (MPL) for the treatment of ALS, has shown positive Phase 1 study results and is gearing up for a pivotal trial anticipated to commence in late 2024. Investors and shareholders are directed to the Pharmaust Investor Hub for further information and updates regarding the AGM and other company matters.
For further insights into AU:PAA stock, check out TipRanks’ Stock Analysis page.
